Quest Diagnostics Inc Business Acquisition, Pro Forma Net Income (Loss)
Quest Diagnostics Inc (DGX) reported Business Acquisition, Pro Forma Net Income (Loss) of $869.00 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2026-02-26
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for the quarter ending 2024-12-31 was $222.00M, a 22.65% increase year-over-year.
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for the quarter ending 2024-09-30 was $222.00M, a 1.33% decline year-over-year.
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for the quarter ending 2024-06-30 was $234.00M.
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for the quarter ending 2024-03-31 was $191.00M.
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for fiscal 2024 was $869.00M, a 3.21% increase from fiscal 2023.
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for fiscal 2023 was $842.00M.
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for fiscal 2014 was $585.00M, a 31.58% decline from fiscal 2013.
- Quest Diagnostics Inc business acquisition, pro forma net income (loss) for fiscal 2013 was $855.00M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2024-12-31 | $222.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $444.00M derived: sum of 2 quarters · filed 2026-02-26 | $678.00M derived: sum of 3 quarters · filed 2026-02-26 | $869.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $222.00M 10-Q · filed 2025-10-21 | $456.00M derived: sum of 2 quarters · filed 2025-10-21 | $647.00M 10-Q · filed 2025-10-21 | $828.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $234.00M 10-Q · filed 2025-07-23 | $425.00M 10-Q · filed 2025-07-23 | $606.00M derived: sum of 3 quarters · filed 2026-02-26 | $831.00M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $191.00M 10-Q · filed 2025-04-23 | $372.00M derived: sum of 2 quarters · filed 2026-02-26 | $597.00M derived: sum of 3 quarters · filed 2026-02-26 | |
| 2023-12-31 | $181.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $406.00M derived: sum of 2 quarters · filed 2026-02-26 | $842.00M 10-K · filed 2026-02-26 | |
| 2023-09-30 | $225.00M 10-Q · filed 2024-10-23 | $661.00M 10-Q · filed 2024-10-23 | ||
| 2014-12-31 | $195.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-22 | $333.00M derived: sum of 2 quarters · filed 2017-02-22 | $476.00M derived: sum of 3 quarters · filed 2017-02-22 | $585.00M 10-K · filed 2017-02-22 |
| 2014-09-30 | $138.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-10-30 | $281.00M derived: sum of 2 quarters · filed 2014-10-30 | $390.00M 10-Q · filed 2014-10-30 | $542.00M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-06-30 | $143.00M 10-Q · filed 2014-07-31 | $252.00M 10-Q · filed 2014-07-31 | $404.00M derived: sum of 3 quarters · filed 2016-02-26 | $821.00M derived: sum of 4 quarters · filed 2016-02-26 |
| 2014-03-31 | $109.00M 10-Q · filed 2015-04-30 | $261.00M derived: sum of 2 quarters · filed 2016-02-26 | $678.00M derived: sum of 3 quarters · filed 2016-02-26 | $841.00M derived: sum of 4 quarters · filed 2016-02-26 |
| 2013-12-31 | $152.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $569.00M derived: sum of 2 quarters · filed 2016-02-26 | $732.00M derived: sum of 3 quarters · filed 2016-02-26 | $855.00M 10-K · filed 2016-02-26 |
| 2013-09-30 | $417.00M 10-Q · filed 2014-10-30 | $580.00M derived: sum of 2 quarters · filed 2014-10-30 | $703.00M 10-Q · filed 2014-10-30 | |
| 2013-06-30 | $163.00M 10-Q · filed 2014-07-31 | $286.00M 10-Q · filed 2014-07-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LABCORP HOLDINGS INC. (LH) | United States | $25.060B | 22.60 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |